Asthma Disease Market Report 2026

The asthma disease market size has grown strongly in recent years. It will grow from $25.93 billion in 2025 to $27.29 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to limited awareness of asthma management, reliance on rescue medications, lack of advanced biologics, insufficient homecare infrastructure, growing urban pollution levels.

The asthma disease market size is expected to see steady growth in the next few years. It will grow to $33.11 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to development of novel biologics and combination therapies, increasing adoption of controller medications, expansion of specialty clinics and homecare services, rising patient awareness and education programs, integration of digital health monitoring and smart inhaler technologies. Major trends in the forecast period include rising prevalence of asthma worldwide, increasing adoption of inhalation therapies, growth in biologics and targeted treatments, expansion of homecare and specialty clinics, focus on personalized and precision medicine approaches.

The increasing prevalence of respiratory disorders is anticipated to drive the growth of the asthma disease market in the coming years. Respiratory disorders encompass a range of conditions that affect the lungs and breathing, including chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. The rising incidence of respiratory disorders is largely attributed to exposure to particulate matter and nitrogen oxides, which irritate and inflame the airways, leading to breathing difficulties and the worsening of conditions such as asthma. Respiratory diseases often cause airway inflammation and structural changes, which can trigger or intensify asthma symptoms. For instance, in December 2023, according to the National Library of Medicine, a US-based national library, projections indicate that by 2050, COPD cases in low- and middle-income countries will more than double compared to those in high-income nations, with sub-Saharan Africa expected to experience a 59% increase and emerge as a global leader in COPD prevalence and case numbers by 2040. Therefore, the rising prevalence of respiratory disorders is contributing to the growth of the asthma disease market.

Major companies operating in the asthma disease market are increasingly focusing on advanced solutions such as integrated Bluetooth-enabled sensor inhalers to improve medication adherence, enable real-time usage tracking, and support personalized disease management. Integrated Bluetooth-enabled sensor inhalers are equipped with digital sensors that connect to smartphone applications, allowing patients to track inhaler usage, receive adherence reminders, and generate data that supports improved symptom monitoring and management. For instance, in July 2023, Teva Pharmaceutical Industries Limited, an Israel-based pharmaceutical company, launched the GoResp Digihaler (budesonide and formoterol) in the UK as Europe’s first fully integrated digital inhaler system for asthma and chronic obstructive pulmonary disease. Manufactured in Ireland, the inhaler features built-in sensors that detect and record inspiratory flow and usage quality and pairs with a patient-facing mobile application that categorizes inhalation performance as good, fair, or low or none. The app also enables report sharing with healthcare professionals via email or clinician dashboards and provides medication reminders to promote consistent therapy adherence, while giving clinicians deeper insights into individual inhalation technique and adherence behavior for more personalized interventions.

In January 2024, GSK plc, a UK-based pharmaceutical company, acquired Aiolos Bio Inc. for an undisclosed amount. Through this acquisition, GSK aims to strengthen its respiratory treatment portfolio and support long-term growth by combining Aiolos Bio’s innovative asthma therapies with GSK’s global capabilities to better serve patients worldwide. Aiolos Bio Inc. is a US-based clinical-stage biopharmaceutical company focused on asthma treatment.

Major companies operating in the asthma disease market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Cipla Limited.

North America was the largest region in the asthma disease market in 2025. The regions covered in the asthma disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the asthma disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the asthma disease market by increasing the cost of imported pharmaceuticals, inhalation devices, and biologics. Controller medications, rescue medications, and biologic therapies are particularly impacted, with regions like Asia-Pacific and Latin America experiencing significant price fluctuations due to import duties. While tariffs have temporarily increased treatment costs, they have also encouraged local manufacturing, partnerships with regional pharmaceutical companies, and investment in domestic production of inhalers and biologics, supporting long-term market growth.

The asthma disease market research report is one of a series of new reports that provides asthma disease market statistics, including asthma disease industry global market size, regional shares, competitors with a asthma disease market share, detailed asthma disease market segments, market trends and opportunities, and any further data you may need to thrive in the asthma disease industry. This asthma disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Asthma disease is a chronic inflammatory condition of the airways marked by recurring episodes of wheezing, shortness of breath, chest tightness, and coughing, especially during the night or in the early morning. It is characterized by airflow obstruction that is often reversible either naturally or with treatment and is linked to airway hyperresponsiveness to triggers such as allergens, physical activity, or cold air.

The main treatment types for asthma disease include controller medications, rescue medications, biologics, and combination therapies. Controller medications are long-term treatments taken daily to prevent asthma symptoms and reduce the frequency of attacks. Asthma can arise from multiple causes, including allergic asthma, non-allergic asthma, exercise-induced asthma, and occupational asthma. The condition is classified by severity into mild intermittent, mild persistent, moderate persistent, and severe persistent. Treatments are administered through various routes such as oral, inhaled, intravenous, and others, and are used by end users including hospitals, home care settings, specialty clinics, and others.

The asthma disease market consists of revenues earned by entities by providing services such as diagnosis, screening, allergy testing, immunotherapy, education, counselling, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma disease market also includes sales of peak flow meters, spirometers, allergy medications, biologic drugs, air purifiers, humidifiers, smart inhalers, wearable asthma monitors, and allergen-proof bedding. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.